Division of Hematology News

Alexis Anne Thompson, MD, to fulfill new leadership role, bringing with her expertise in blood disorders and clinical practice.

Results from multicenter study are first to show improved production of coagulation factor VIII over prolonged period, leading to reduction or complete elimination of bleeding events.

A collaborative team of researchers, including Dr. Stephan Grupp, recently presented preliminary data showing that a CRISPR-based gene-editing therapy for inherited blood disorders is safe and effective.

Kwaku Ohene-Frempong, MD was named a 2021 Honorific Award Recipient by the American Society of Hematology.

CHOP researchers have developed a proof-of-concept treatment for blood disorders like sickle cell disease that elevates both fetal and adult hemoglobin.

CHOP researchers were interviewed as a part of a comprehensive article about cell and gene therapy in Philadelphia Magazine.

CHOP researchers have identified BAFF as a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.

The findings identify possible targets for future therapies for ribosomopathies, childhood disorders that lead to bone marrow failure (BMF).

CHOP researchers have developed a gene therapy vector for sickle cell disease and other blood disorder that is potentially superior to competitors.

CHOP researchers identified an in vivo role for activated protein C (APC), which could potentially be exploited for future hemophilia A treatments.